Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897439 · ClinicalTrials.gov registry record · Phase 3
Individualizing Pharmacotherapy for African American Smokers
A Phase 3 study of Smoking Cessation, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 392
- Enrollment target
- 1
- Study location
NCT03897439: Completed Phase 3 study of Smoking Cessation, sponsored by University of Kansas Medical Center.
NCT03897439 is a Phase 3 study of Smoking Cessation that has completed, run by University of Kansas Medical Center. The registered enrollment target is 392 participants, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03897439, a Phase 3 study of Smoking Cessation, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 392 participants
- Enrollment target
- 1
- Study location
Study Summary
Improving cessation outcomes for African American smokers through the use of novel, empirically-based strategies is a national health priority. In the vast majority of smoking cessation studies and in clinical practice, when smokers are provided a medication to help them quit, they are expected to continue that medication regardless of how well it is working. This study will assess whether African Americans smokers respond better if they continue with a single treatment or if their treatment is changed when that treatment is not working.
Primary Outcome
Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Week 12 visit. This will evaluate the short-term efficacy of optimized pharmacotherapy for smoking cessation in African American smokers.
Conditions Studied
Interventions
- DRUG Varenicline Tartrate
- DRUG Bupropion
- DRUG Nicotine patch
Study Locations (1)
Missouri
- Swope Health Central - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2022-01-30 |
| Phase | Phase 3 |
What the finished NCT03897439 record still lists
NCT03897439 is an interventional study that assigns participants to a tested intervention. The registered 392 participants enrollment target is mid-sized for trials with a published cap, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 3 interventions - of which Varenicline Tartrate is the first listed.
NCT03897439 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03897439 about?
NCT03897439 is a clinical study titled "Individualizing Pharmacotherapy for African American Smokers". Improving cessation outcomes for African American smokers through the use of novel, empirically-based strategies is a national health priority. In the vast majority of smoking cessation studies and in clinical practice, when smokers are provided a medication to help them quit, they are expected to c...
What is the current status of trial NCT03897439?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 392 participants. The study started on 2019-05-01. Estimated completion is 2022-01-30.
What conditions does trial NCT03897439 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT03897439?
The interventions under investigation include: Varenicline Tartrate (DRUG), Bupropion (DRUG), Nicotine patch (DRUG).
Who is sponsoring clinical trial NCT03897439?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03897439 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03897439's enrollment target sits among peer trials
392 70th of 188 higher than 119 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI